Agitation

Is Sundown Syndrome Taking Over Your Evenings? Michele Nealon, Psy.D. Shares Expert Tips to Manage the Symptoms

Retrieved on: 
Tuesday, April 9, 2024
Health, Agitation, Sleep apnea, Alzheimer's disease, Confusion, Exercise, Chicago school, Hunger, Depression, Caregiver, Diabetes, Empathy, Stroke, Sleep, Mental health, Sundowning, Anxiety, Frustration, Dementia, Medicine, Residential care

Sundown syndrome is a state of confusion or agitation that comes on in the late afternoon and worsens into the night, preventing the person from getting sleep.

Key Points: 
  • Sundown syndrome is a state of confusion or agitation that comes on in the late afternoon and worsens into the night, preventing the person from getting sleep.
  • This syndrome's cause is not well understood, but we know it can take a toll on the individual and their caregivers.
  • Setting a schedule of regular exercise, a healthy diet, and quality sleep for you and the person you are taking care of is imperative.
  • Patience and empathy are key when trying to ease their agitation because it can worsen if they sense your frustration.

IGC Pharma Adds Advisor in Artificial Intelligence

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Other Technology, Research, Artificial Intelligence, Science, Clinical Trials, Diagnosis, Agitation, Biomedicine, Mathematics, Universidad, Algorithm, Biomedical engineering, Paris Dauphine University, Risk, Patient, Artificial intelligence, AI, University, Deep learning, Universidad de los Andes, Computer vision, IGC, GxP, Dementia, Medical device

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.

Key Points: 
  • IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers.
  • This will help IGC Pharma identify individuals who are most likely to respond to treatment and accelerate the delivery of treatments to patients.
  • Pablo Arbeláez is a distinguished researcher with over 20 years of experience in Computer Vision and Artificial Intelligence.
  • Ram Mukunda, CEO of IGC Pharma, stated, "We welcome Dr. Pablo Arbelaez to our team of Senior Advisors.

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Retrieved on: 
Friday, March 15, 2024
The Orange Book, Agitation, Patent, Intelligence, Patient, Tablet, Heel, EPO, Orange Book, Therapy, European Patent Convention, Dexmedetomidine, FDA, Dementia, Pharmaceutical industry

The 486 patent covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia.

Key Points: 
  • The 486 patent covers the use of dexmedetomidine administered sublingually to treat agitation in individuals with dementia.
  • The patent encompasses a broad range of dosage forms, including films such as BXCL501 (sublingual dexmedetomidine), wafers, and tablets, at dexmedetomidine doses ranging from 3 mcg to 100 mcg.
  • 17/496,470 with claims pertaining to methods of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form.
  • The patent, when issued, is expected to have an expiration date of July 17, 2040, subject to patent term adjustment, patent term extension, and terminal disclaimers.

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, March 12, 2024
The Orange Book, Patent Cooperation Treaty, Agitation, Administration, Conference call, Type, PCT, Conference, Database, Schizophrenia, Intelligence, Caregiver, Webcast, Patient, DSM-IV codes, Neuroscience, Fast Track, Food and Drug Administration, CMC, Wind, Orange Book, SCNC, Positive, Microsatellite instability, Dexmedetomidine, Clinical trial, Therapy, Safety, Patent, Research and development, Collection, FDA, Approved drug, Dementia, CAD, Food, Pharmaceutical industry

NEW HAVEN, Conn., March 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today provided an update on its late-stage TRANQUILITY and SERENITY clinical programs. In addition, the Company reported its financial results for the fourth quarter and full year 2023.

Key Points: 
  • In addition, the Company reported its financial results for the fourth quarter and full year 2023.
  • Net Revenue: Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.
  • Net Loss: BioXcel Therapeutics had a net loss of $22.3 million for the fourth quarter of 2023, compared to a net loss of $54.8 million for the same period in 2022.
  • ET to provide an update on recent operational highlights and to discuss its fourth quarter and full year 2023 financial results.

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, Technology, Health, General Health, Pharmaceutical, Mental Health, Other Science, Other Technology, Research, Science, Clinical Trials, Agitation, AD1, Alzheimer's disease, Patient, CMAI, IGC, AAD, Caregiver burden, Dementia, Food, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).
  • The interim data demonstrates a clinical and statistically significant reduction in agitation compared to placebo in patients with Alzheimer’s disease, indicating strong therapeutic potential for IGC-AD1.
  • "We are excited with the positive interim results from the Phase 2 trial of IGC-AD1 for agitation in dementia due to Alzheimer's disease.
  • IGC-AD1’s interim results demonstrate a clinical and statistically significant reduction in agitation compared to placebo, suggesting a strong plausibility to address a substantial unmet medical need.

Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

Retrieved on: 
Monday, March 18, 2024
Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Week, Psychosis, Agitation, Commercialization, Medication, Psychiatry, Caregiver, Patient, Geriatric psychiatry, Overalls, MD, Lundbeck, NPI, CMAI, Neuropsychiatry, Safety, Poster, Behavioral neuroscience, Multimedia, Dementia, Annual general meeting, Food

One poster utilized the Neuropsychiatric Inventory (NPI) to explore the relationship of REXULTI on neuropsychiatric symptoms relating to agitation and occupational disruptiveness/caregiver distress related to patients’ behavior.

Key Points: 
  • One poster utilized the Neuropsychiatric Inventory (NPI) to explore the relationship of REXULTI on neuropsychiatric symptoms relating to agitation and occupational disruptiveness/caregiver distress related to patients’ behavior.
  • The NPI, which is administered through a structured caregiver interview, is comprised of 12 domains of neuropsychiatric symptoms including agitation/aggression, irritability/lability, and disinhibition.
  • The analysis demonstrated that REXULTI was associated with reductions in overall neuropsychiatric symptoms and in agitation symptoms (as captured by the NPI) compared with placebo over 12 weeks.
  • “The breadth of data presented at AAGP represents our continued commitment to understanding the full potential of REXULTI on agitation associated with dementia due to Alzheimer’s disease.”

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Technology, Pharmaceutical, Mental Health, Infectious Diseases, Neurology, Artificial Intelligence, Clinical Trials, Other Technology, Science, Biotechnology, Alternative Medicine, Other Science, Health, Research, NCI, Agitation, Patient, Committee, National Cancer Institute, Virology, University, Quality of life, NIH, House, Myenteric plexus, Pancreatic Cancer Action Network, University of Maryland, Baltimore, Fetal alcohol spectrum disorder, IGC, IHV, Pharma, Jan Vansina, Bangladesh Technical Education Board, Therapy, Senate, Dementia, Public affairs, Pharmaceutical industry

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.

Key Points: 
  • IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.
  • Terry founded the Children’s Research Institute, one of America's top children’s research programs, the Pancreatic Cancer Action Network (PanCAN), and the National Organization on Fetal Alcohol Syndrome (NOFAS).
  • Ram Mukunda, CEO of IGC Pharma, commented, “With his track record of execution and extensive experience in health care, Mr. Lierman will undoubtedly bring invaluable insights and strategic guidance to IGC Pharma.
  • I look forward to collaborating with the talented team at IGC Pharma to drive forward the mission of bringing transformative therapies to patients in need.”

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Monday, February 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 20, 2024
Shift, Acquisition, DSM-IV codes, Fibromyalgia, Central nervous system, Total, New Drug Application, MD, Narcolepsy, FDA, Marketing, Smoking, Food, Somnolence, Growth, SYMPHONY, Reboxetine, Psychiatry, Dextromethorphan/bupropion, Migraine, FOCUS, Safety, Therapy, Medicare, NMDA, CNS, Food and Drug Administration, BED, Webcast, Depression, Binge eating disorder, Patient, Agitation, Shirin David, Medicaid, SWD, Breakthrough therapy, MDD, NDA, Prescription, Pharmaceutical industry

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

Retrieved on: 
Wednesday, February 28, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Acquisition, Neuropharmacology, Morris water navigation task, Dementia, Neuroscience, MWM, Amnesia, IGC, Spatial navigation, Deficit spending, Peptide, Memory, Spatial memory, Patient, LTP, Agitation, Mouse

The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Key Points: 
  • The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.
  • Ram Mukunda, CEO, commented, "These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer's disease model, offering promising implications for potential therapeutic interventions in Alzheimer's and related neurodegenerative conditions.
  • The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer's Disease.
  • The NOR Test, a cornerstone of preclinical research, evaluates recognition memory, a component of declarative memory responsible for recognizing previously encountered stimuli.